# TELESTO (NCT00940602)

> Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

No report yet. It can be ordered.

- Drugs tested: deferasirox
- Indication: transfusion-dependent low- to intermediate-1-risk myelodysplastic syndromes

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00940602
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Novartis Pharmaceuticals
- Conditions: Myelodysplastic Syndromes
- Interventions: Deferasirox; Placebo
- Enrollment: 225
- Primary outcome: Event-free Survival

## Indexed commentary on TELESTO so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 YouTube videos
- 3 podcast episodes
- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=telesto-nct00940602

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00940602", "email": "<work email>"}; the inbox owner confirms by the emailed link.